Rare disease drugmaker · part of Merck KGaA, Darmstadt, Germany · based in Stamford, United States · springworkstx.com
SpringWorks Therapeutics, Inc. works on 3 rare diseases we track, including Desmoid Tumors, Mesothelioma and 1 more. It has 4 active clinical trials, and 2 are looking for volunteers now. It also has 2 FDA-approved rare disease drugs.
SpringWorks Therapeutics is a rare tumor company based in Stamford, Connecticut, and part of Merck KGaA, Darmstadt, Germany since July 1, 2025.
SpringWorks Therapeutics, Inc. pipeline
Each row lists the diseases SpringWorks Therapeutics, Inc. is studying at that stage, from the ones closest to approval down to the earliest work.
These are SpringWorks Therapeutics, Inc. trials for the rare diseases we track, from ClinicalTrials.gov. Statuses there can lag behind company news, so confirm with the study team before you plan around one.
2 trials looking for volunteers now
Looking for volunteersPhase 1Recently updatedNCT06251310
This is a first-in-human (FIH), Phase 1a/1b open-label, multicenter, dose escalation and dose expansion study of SW-682 in adult participants with metastatic or unresectable advanced solid tumors with or without Hippo pathway alterations that are refractory to, or have progressed, during or after appropriate prior systemic anticancer therapy, including chemotherapy, immunotherapy, radiation therapy or targeted therapy, or for which no treatment is available, or prior standard of care (SOC) therapy was not tolerated and for which there is no further SOC treatment available. The study includes a Part 1 (Phase 1a) dose escalation phase and a Part 2 (Phase 1b) dose expansion to optimize the dose to be used for further development. All participants will self-administer SW-682 by mouth in 28-day cycles.
This study is being conducted to study how nirogacestat may affect the ovarian function of adult premenopausal women with progressing desmoid tumors/aggressive fibromatosis.
This study evaluates mirdametinib (PD-0325901) in the treatment of symptomatic inoperable neurofibromatosis type-1 (NF1)-associated plexiform neurofibromas (PNs). All participants will receive mirdametinib (PD-0325901). Eligible participants may continue in a long-term follow-up phase.
This study is being conducted to characterize the efficacy and safety of nirogacestat in Japanese adults with progressing desmoid tumors/aggressive fibromatosis.
Follow a condition SpringWorks Therapeutics, Inc. is studying
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only SpringWorks Therapeutics, Inc.. Unsubscribe anytime.
You'll get, for Desmoid Tumors:
Trial Alerts, when a new trial opens or a trial changes
Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
For Desmoid Tumors. Approved Nov 27, 2023. Taken by mouth.
More about SpringWorks Therapeutics, Inc.
It sells Ogsiveo (nirogacestat), approved by the FDA on November 27, 2023 as the first treatment for adults with progressing desmoid tumors who need systemic treatment, and Gomekli (mirdametinib), approved on February 11, 2025 for adults and children 2 and older with symptomaticneurofibromatosis type 1 plexiform neurofibromas that cannot be fully removed by surgery.
It is testing mirdametinib in infants and toddlers with NF1 and an early-stage drug, SW-682, in advanced solid tumors including mesothelioma.
Where SpringWorks Therapeutics, Inc. trials take place
The trials above run at 77 study sites in 8 countries. Tap a country to see its states, cities and hospitals.
United States
51▼
Spain
8▼
Italy
7▼
United Kingdom
4▼
Japan
3▼
Netherlands
2▼
Belgium
1▼
Germany
1▼
Rare diseases SpringWorks Therapeutics, Inc. works on
Each disease page lists every open trial, not only SpringWorks Therapeutics, Inc.'s, plus approved treatments.
Neurofibromatosis type 1 is a genetic disorder caused by mutations in the NF1 gene on chromosome 17, which encodes neurofibromin, a tumor suppressor protein.
How common: 1 in 2,500 to 3,500 people in the U.S., making it one of the most common genetic conditions
Where to get support
Patient groups can explain a diagnosis, point you to specialists and tell you about trials before they open. SpringWorks Therapeutics, Inc.'s own site is springworkstx.com, and our help paying for treatment page lists drugmaker programs and charity funds.
Yes, of Merck KGaA, Darmstadt, Germany, which is a different company from the US drugmaker Merck & Co. Merck KGaA completed its purchase of SpringWorks on July 1, 2025, paying $47 a share in cash, and SpringWorks stock stopped trading on Nasdaq.
Labels: the Ogsiveo label is still issued by SpringWorks Therapeutics in Stamford, Connecticut.
Ogsiveo (nirogacestat): a gamma secretase inhibitor approved on November 27, 2023 for adults with progressing desmoid tumors who need systemic treatment, the first treatment approved for this tumor.
Gomekli (mirdametinib): a MEK inhibitor approved on February 11, 2025 for adults and children 2 and older with neurofibromatosis type 1plexiform neurofibromas that cause symptoms and cannot be fully removed by surgery. See the Gomekli page.
In trials: mirdametinib in infants and toddlers with NF1 plexiform neurofibromas (NCT07850635), and SW-682 in advanced solid tumors including mesothelioma (NCT06251310).
SpringWorks Therapeutics, Inc. has active programs across 3 rare diseases: Desmoid Tumors, Mesothelioma, Neurofibromatosis Type 1. Each disease page on Trial Friend shows the latest recruiting trials, FDA-approved treatments, and patient resources.
The clinical trials section on this page shows active and recruiting rare disease trials sponsored by SpringWorks Therapeutics, Inc., pulled live from ClinicalTrials.gov. Each trial card includes the study phase, recruitment status, conditions being studied, number of trial sites, and a direct link to the full study record. You can also explore individual disease pages to see trials from all sponsors for a specific condition.
To explore enrollment, find a recruiting trial in the clinical trials list on this page and click "View full study" to see the full ClinicalTrials.gov record, which includes eligibility criteria, study locations, and contact information for each trial site. Your doctor can also help determine if a specific trial is appropriate for your condition. Not all trials are open at every location, so check the site list for one near you.
SpringWorks Therapeutics, Inc. has 2 FDA-approved drugs with a rare disease use that we track, as of November 2026.
Source: the FDA's openFDA label database, matched to the rare diseases on Trial Friend; the list updates automatically and can include older products.
Yes, for 2 of its FDA-approved rare disease medicines that we track, each checked on SpringWorks Therapeutics, Inc.'s own website.
Gomekli: SpringWorks CareConnections, 844-227-3755. Offers copay help with private insurance, a free medicine program and insurance help. Checked September 24, 2026.
Ogsiveo: SpringWorks CareConnections, 844-227-3755. Offers copay help with private insurance and insurance help. Checked November 2, 2026.
Medicare and Medicaid: drugmaker copay cards are limited to private insurance, so people with government coverage usually look to a free medicine program or a charity fund, both on the help paying page.
Eligibility is decided by each program, so call the number listed before a prescription is filled.